This study is designed to evaluate the relative bioavailability (rBA) of multiple test tablet formulations of BMS-986435 compared to an equal dose of the BMS-986435 reference tablet formulation. The effect of food on the drug levels of selected BMS-986435 tablet formulations will also be evaluated.
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria
* Participants must have a body weight of ≥ 45 kg and BMI between 18 and 32 kg/m2, inclusive
* Participants must be healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), clinical laboratory assessments
* Participants must have documented left ventricular ejection fraction (LVEF) ≥ 60% and absence of significant cardiac abnormality at screening, as determined by local transthoracic echocardiogram (TTE) assessment
* Other protocol-defined Inclusion/Exclusion criteria apply
Primary outcome measure(s)
Maximum observed concentration (Cmax) — Up to Day 28
Area under the concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) — Up to Day 28
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) — Up to Day 28
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.